Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 18/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275824 | 0.84 | NR3C1 (0.54) | NR3C1CYP11B1CYP11B2 | |
| SCHEMBL4281591 | 0.84 | NR3C1 (0.54) | NR3C1CYP11B1CYP11B2 | |
| SCHEMBL4274030 | 0.82 | NR3C1 (0.53) | NR3C1CYP11B1CYP11B2 | |
| SCHEMBL4283384 | 0.81 | NR3C1 (0.54) | NR3C1CYP11B1CYP11B2PGR | |
| SCHEMBL4281479 | 0.81 | NR3C1 (0.54) | NR3C1CYP11B1CYP11B2PGR | |
| SCHEMBL4273512 | 0.81 | NR3C1 (0.54) | NR3C1CYP11B1CYP11B2PGR | |
| SCHEMBL4274237 | 0.81 | NR3C1 (0.65) | NR3C1PGR | |
| SCHEMBL13610591 | 0.79 | NR3C1 (0.54) | NR3C1CYP11B1CYP11B2 | |
| SCHEMBL4280464 | 0.79 | NR3C1 (0.56) | NR3C1CYP11B1CYP11B2 | |
| SCHEMBL4277849 | 0.79 | NR3C1 (0.55) | NR3C1CYP11B1CYP11B2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893588-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2008-03-05 | — | — | EP | claimed |
| US-20070060633-A1 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | claimed |
| WO-2006135826-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-21 | — | — | WO | claimed |
| US-7622594-B2 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622594-B2 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622594-B2 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1893588-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2008-03-05 | — | — | EP | disclosed |
| US-20070060633-A1 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060633-A1 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| WO-2006135826-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060633-A1 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, MC2R, NR3C2 | NR3C1 1/4885CYP11B1 24/4885CYP11B2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.